Received Apr 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | 3 | Y010035 | IM / LA |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | Y011017 | SC / UN |
04 April 2025: 18 month old received Varivax (dose 1) and PCV-15 (dose 3) 09 April 2025: T102.8, emesis x 2, rash to neck and back; decreased appetite. Father reported that he had "varicella" 2 weeks ago, was evaluated at another hospital. 10 April 2025: presented to ED, afebrile with exam performed and documented by NP; noted "shallow ulcerations to palate, generalized vesicopustular rash to face, trunk, and extremities, sparing palms and soles". Discharged 10 April 2025 11 April 2025: represented to ED with continued temp of 102, responds to antipyretics and recurs. Evaluated by MD. Parents reported lesions started on back. Lesions have a red base, vesiculopustular, scabbing, pruritic. Decreased appetite. Administered diphenhydramine; one palatal ulcer noted; lesions diffuse over trunk, extremities, face, near eyes, no scleral or conjunctival involvement. Discharged 11 April 2025. Per my assessment as the hospital epidemiologist, I recommended reporting to VAERS as it is unclear if this is wild-type varicella from exposure to the father or varicella-vaccine associated. No diagnostic testing was done at either ED encounter. PCP declined to complete the VAERS form, as by report, he did not feel that the child's lesions and ED presentations x 2 were vaccine associated.
hemangiona reported
no prescription
none reported
None